Tirzepatide Guide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist that activates two incretin hormone pathways simultaneously. It is FDA-approved for type 2 diabetes as Mounjaro and for chronic weight management as Zepbound, and has demonstrated superior weight loss outcomes compared to semaglutide in head-to-head trials.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
At a Glance
How Tirzepatide Works
Tirzepatide is a "twincretin" that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. GLP-1 activation reduces appetite and slows gastric emptying, while GIP activation enhances insulin secretion, reduces glucagon, and may also act directly on fat tissue to improve metabolism. This dual mechanism produces greater weight loss than GLP-1-only agents like semaglutide.[3][5]
Dosing Schedule
Tirzepatide uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].
Side Effects
Common: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, injection site reactions, fatigue. Serious (rare): pancreatitis, gallbladder problems, hypoglycemia (especially with insulin), kidney problems, increased heart rate. Same thyroid tumor precautions as semaglutide apply.[1][3]
This is not a complete list. Consult your healthcare provider or prescriber for full safety information. The complete adverse reaction profile is published in the current FDA prescribing information[1].
Clinical Trial Results
In the SURMOUNT-1 trial (N=2,539), tirzepatide at the 15mg dose achieved an average weight loss of 22.5% over 72 weeks — nearly double the results seen with semaglutide. Participants on 10mg lost an average of 21.4%, and those on 5mg lost 15.0%, all versus 2.5% placebo.[3][4]
Where to Get Tirzepatide
These telehealth providers offer access to tirzepatide or compounded equivalents with online consultations and home delivery.
Editorial score · methodology
Editorial score · methodology
Enhance MD
Best for: lab-monitored compounded GLP-1 with mandatory video visit
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Pallas Health
Best for: the most complete public disclosure of pharmacies and prescribing physicians we have found
Editorial score · methodology
Cost Comparison
Starting prices for compounded GLP-1 medications from top providers, sorted cheapest first. Compounded tirzepatide from licensed 503A and 503B pharmacies is legal under federal compounding law[6], with additional tolerances historically allowed while the molecule has appeared on the FDA Drug Shortage List[7]. Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502[8]. Prices may vary based on dose and promo availability.
Tirzepatide Head-to-Head Comparisons
Short-form verdict pages comparing Tirzepatide to other GLP-1 options with trial-anchored data, FDA-label dosing, and current manufacturer pricing.
See all drug-vs-drug verdicts.
Pivotal Tirzepatide Trial Walkthroughs
Endpoint-by-endpoint breakdowns of the trials that shaped the Tirzepatide label, with primary-source numbers and FAQs.
Tirzepatide Patient Questions, Answered
Real patient questions about Tirzepatide pulled from named subreddits and answered with peer-reviewed trial data.
Ranked PubMed Studies on Tirzepatide
Curated lists of the highest-impact peer-reviewed studies on Tirzepatide and related GLP-1 drugs. Every PMID live-verified via PubMed esummary.
Related Research on Tirzepatide
Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.
Frequently Asked Questions
Sources & methodology — as of August 2026
- 1.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 2.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 3.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 4.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 5.ADA — Standards of Care in Diabetes (2025)— American Diabetes Association.
- 6.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 7.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 8.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Zepbound · Drugs and brands
- Mounjaro · Drugs and brands
- GLP-1 receptor · Mechanism
- GIP receptor · Mechanism
- Dual agonist · Mechanism
- SURMOUNT-1 · Major trials
- SURMOUNT-OSA · Major trials
- Compounded GLP-1 · Pharmacy and drug forms
- Titration · Dosing